Group 1 - The core viewpoint of the article highlights the significant stock price increase of Basilea Pharmaceutica (02616), which rose over 9% in early trading and is currently up 6.11% at HKD 7.29, with a trading volume of HKD 12.048 million [1] - GIC has increased its stake in Basilea Pharmaceutica to 6% as of October 13, marking its second substantial purchase in less than two months, having previously acquired 80.4 million shares for over HKD 630 million on August 18 [1] - The European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Sugliatinib as a monotherapy for adult patients with unresectable stage III non-small cell lung cancer (NSCLC) who have PD-L1 expression ≥1% and have not progressed after platinum-based chemoradiotherapy [1]
港股异动 | 基石药业-B(02616)早盘涨超9% GIC时隔近两月再度增持公司股份 持股比例已达到6%